Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 28;19(19):12366.
doi: 10.3390/ijerph191912366.

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Gyeyoung Choi  1 , Gyeongseon Shin  1 , SeungJin Bae  1
Affiliations

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Gyeyoung Choi et al. Int J Environ Res Public Health. .

Abstract

Although chimeric antigen receptor (CAR) T-cell therapy has shown a high response rate in lymphoma patients, its cost-effectiveness is controversial due to the high price and uncertainty of the clinical evidence. In addition to the high acquisition cost of CAR T-cell therapy, procedure and facility cost increase the financial burden considering the frequency of adverse events such as cytokine release syndrome. In clinical research, relatively short follow-up periods were used compared to traditional cancer agents. In addition, head-to-head comparative effectiveness data are unavailable, which is an important factor when evaluating the cost-effectiveness of a new treatment. Additional evidence that will compensate for the uncertainty of existing clinical data is needed for full evaluation of long-term efficacy, safety, and comparative effectiveness.

Keywords: CAR T-cell; chimeric antigen receptor T-cell therapy; economic evaluation; value.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Borgert R. Improving Outcomes and Mitigating Costs Associated with CAR T-Cell Therapy. Am. J. Manag. Care. 2021;27:S251–S261. - PubMed
    1. Rafiq S., Hackett C.S., Brentjens R.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 2020;17:147–167. doi: 10.1038/s41571-019-0297-y. - DOI - PMC - PubMed
    1. Xu D., Jin G., Chai D., Zhou X., Gu W., Chong Y., Song J., Zheng J. The development of CAR design for tumor CAR-T cell therapy. Oncotarget. 2018;9:13991. doi: 10.18632/oncotarget.24179. - DOI - PMC - PubMed
    1. Schuster S.J., Svoboda J., Chong E.A., Nasta S.D., Mato A.R., Anak O., Brogdon J.L., Pruteanu-Malinici I., Bhoj V., Landsburg D., et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N. Engl. J. Med. 2017;377:2545–2554. doi: 10.1056/NEJMoa1708566. - DOI - PMC - PubMed
    1. Locke F.L., Ghobadi A., Jacobson C.A., Miklos D.B., Lekakis L.J., Oluwole O.O., Lin Y., Braunschweig I., Hill B.T., Timmerman J.M., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42. doi: 10.1016/S1470-2045(18)30864-7. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources